South San Francisco, CA, United States

Onyx Pharmaceuticals

www.onyx-pharm.com
South San Francisco, CA, United States

Onyx Pharmaceuticals Inc. is a biopharmaceutical company headquartered in South San Francisco, California. The company develops and markets medicines for the treatment of cancer. Onyx was founded in 1992 by Kevin J. Kinsella and Frank McCormick Ph.D., FRS. In 2009, the company acquired Proteolix, Inc., a private biotechnology company. In January 2012, the company was named "the top biotechnology takeover target in 2012" through an industry survey. Onyx CEO Tony Coles has said Onyx likes it prospects as an independent company and is focused on bringing new therapies to patients. However, at the end of August 2013, Amgen announced it was acquiring Onyx in an agreed $10.4 billion deal.Other backers of Onyx were Avalon Ventures, IVP, J. H. Whitney & Company, and Kleiner Perkins Caufield & Byers. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

News Article | May 4, 2017
Site: globenewswire.com

MENLO PARK, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- GRAIL, Inc., a life sciences company whose mission is to detect cancer early when it can be cured, today announced the appointment of José Baselga, M.D., Ph.D., Brook Byers and Kaye Foster to its Board of Directors. The three new board members will join GRAIL’s existing board of directors: Bill Rastetter, Jeff Huber, Richard Klausner and Robert Nelsen. “I am very pleased to welcome José, Brook and Kaye, three extremely seasoned and accomplished executives, to our Board at this pivotal time for GRAIL,” said Jeff Huber, GRAIL’s Chief Executive Officer. “With these leaders, we are increasing the breadth of strategic leadership, industry experience and operational excellence within our Board. As we work to expand our operations and build integrated programs in science, technology and clinical development, their expertise and counsel will be invaluable. We are looking forward to working with them in our pursuit to transform the way cancer is diagnosed and treated.” José Baselga is the Physician-in-Chief and Chief Medical Officer at Memorial Sloan Kettering Cancer Center (MSK) and Professor of Medicine at Weill Cornell Medical College. Prior to MSK, Dr. Baselga was the Chief of the Division of Hematology/Oncology, Associate Director of the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School. He also was the Chairman of Medical Oncology and Founding Director of the Vall d’Hebron Institute of Oncology in Barcelona, Spain. Dr. Baselga is a past President of the American Association of Cancer Research (AACR) and of the European Society for Medical Oncology, and a past member of the Board of Directors for the American Society of Clinical Oncology (ASCO) and AACR. He is an elected member of the National Academy of Medicine, the American Society of Clinical Investigation, the Association of American Physicians, and a Fellow of the AACR Academy. He is a past member of the Editorial Boards of Cancer Cell, Journal of Clinical Oncology, and Clinical Cancer Research and is the founding editor-in-chief for the AACR flagship journal Cancer Discovery. In addition to joining GRAIL’s Board of Directors, Dr. Baselga is also the Chairman of GRAIL’s Scientific Advisory Board. Dr. Baselga earned his M.D. from Universitat Autonoma de Barcelona and completed residencies in internal medicine at Vall d'Hebron University Hospital and SUNY - Health Sciences Center at Brooklyn. Brook Byers is a senior partner and founding member of the venture capital firm Kleiner Perkins Caufield & Byers (KPCB). Mr. Byers formed the first life sciences practice group in the venture capital profession and led KPCB to become a premier venture capital firm in the medical, healthcare, and biotechnology sectors. Brook has been a pioneer in the fields of precision medicine, molecular diagnostics and genomics, serving as a Steering Committee member for the Coalition of 21st Century Medicine, and through investment and board leadership in companies such as Foundation Medicine, Genomic Health and Veracyte. Brook currently serves on the Board of Directors of Cell Design Labs, Enjoy, Newsela, and Zephyr Health. He also serves on the Board of Overseers of the University of California San Francisco medical campus and hospitals, the Stanford Medicine Advisory Council and the Board of Directors of the New Schools Foundation. Mr. Byers holds a bachelor’s degree in Electrical Engineering from Georgia Institute of Technology and an MBA from Stanford University. He is also the recipient of an honorary Ph.D. from Georgia Institute of Technology. Kaye Foster has over 25 years of experience in the pharmaceutical industry leading large, global human resources organizations. She currently advises CEOs and leadership teams focusing on business transformations, talent management strategy and Human Resources strategy development and implementation. Most recently, she was Senior Vice President, Global Human Resources for Onyx Pharmaceuticals where she led all aspects of human resources for U.S. and global operations. Ms. Foster joined Onyx from Johnson & Johnson where she served as an Executive Committee member and Chief Human Resources Officer, leading a worldwide team of over 3,000 human resources professionals. She also held several Human Resources executive positions with Pfizer Inc., supporting its pharmaceutical businesses in Japan, Asia, Africa, Middle East and Latin America, and she led the integration of both the Warner-Lambert and Pharmacia mergers for these regions. She is a Senior Advisor with The Boston Consulting Group (BCG) and sits on the Board of Directors of Agios Pharmaceuticals as well as the Board of Trustees of Spelman College, Stanford Healthcare, ValleyCare Health System and Glide Memorial Church in San Francisco. Kaye holds a bachelor’s degree from Baruch College and an MBA from Columbia Business School. About GRAIL GRAIL is a life sciences company whose mission is to detect cancer early when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical trials, and state of the art Computer Science and Data Science to enhance the scientific understanding of cancer biology and develop blood tests for early-stage cancer detection. The company’s funding was led by ARCH Venture Partners and includes Amazon, Bezos Expeditions, Bill Gates, Bristol-Myers Squibb, Celgene, GV, Illumina, Johnson & Johnson Innovation, Merck, McKesson Ventures, Sutter Hill Ventures, Tencent, Varian Medical Systems, and other financial partners. For more information, please visit www.grail.com.


News Article | May 12, 2017
Site: marketersmedia.com

Malignant Lymphoma Market Information, by types (Hodgkin lymphoma and Non Hodgkin lymphoma), by treatment (chemotherapy, radiation therapy, immunotherapy, stem cell therapy and others) - Forecast to 2022 Pune, India - May 11, 2017 /MarketersMedia/ — Malignant Lymphoma Market Information, by types (Hodgkin lymphoma and Non Hodgkin lymphoma), by treatment (chemotherapy, radiation therapy, immunotherapy, stem cell therapy and others) - Forecast to 2022 The lymphatic system runs throughout our bodies. Cancers that develop anywhere in body’s lymphatic system are called as lymphoma and if they have the ability to spread in the body, they are called malignant lymphoma. The most common symptom of the lymphoma is swollen glands. Men are more prone to lymphoma compared to women for the reason unknown. Globally the market for malignant lymphoma is increasing rapidly. Get a sample copy @ https://www.marketresearchfuture.com/sample_request/1861 . Study objectives of Malignant Lymphoma Market: • To provide detailed analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the malignant lymphoma market. • To provide insights about factors affecting the market growth • To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc. • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa. • To provide country level analysis of the market with respect to the current market size and future prospective • To provide country level analysis of the market for segments by type, by treatment and its sub-segments. • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global malignant lymphoma market. Complete Report Available at https://www.marketresearchfuture.com/reports/malignant-lymphoma-market . Intended Audience • Malignant lymphoma drug manufacturers & Suppliers • Contract Research Organizations (CROs) • Research and Development (R&D) Companies • Government Research Laboratories • Independent Research Laboratories • Government and Independent Regulatory Authorities • Market Research and Consulting Service Providers • Academic Institutes and Universities Malignant lymphoma market has been segmented on the basis of types which comprises of Hodgkin lymphoma and non-Hodgkin lymphoma. On the basis of treatments, market is segmented into chemotherapy, radiation therapy, immunotherapy, stem cell therapy and others. Globally North America is the largest market for malignant lymphoma. Europe is the second-largest market. Furthermore Asia pacific market is expected to be the fastest growing market for malignant lymphoma. Request for Discount at https://www.marketresearchfuture.com/check-discount/1861 Some of the key players in this market are: • Abbott Laboratories • ABIOGEN PHARMA S.p.A. • Actelion Pharmaceuticals • Aeterna Zentaris, Inc. • Allos Therapeutics • Astellas Pharma • Bristol-Myers Squibb Company • Celgene Corporation • Eli Lilly and Company • Genmab • Inovio Pharmaceuticals • Johnson & Johnson • Merck & Co. Inc. • Novartis • Onyx Pharmaceuticals • Roche • Seattle Genetics North America • US • Canada • Europe Western Europe • Germany • France • Italy • Spain • UK • Rest of Western Europe • Eastern Europe Asia • China • India • Japan • South Korea • Rest of AsiaPacific Middle East & Africa The report for Malignant Lymphoma Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions List of Tables TABLE 1 GLOBAL MALIGNANT LYMPHOMA MARKET, BY TYPES, 2013-2022 (USD MILLION) TABLE 2 GLOBAL MALIGNANT LYMPHOMA MARKET, BY TREATMENT, 2013-2022 (USD MILLION) TABLE 3 GLOBAL MALIGNANT LYMPHOMA MARKET, BY REGION, 2013-2022 (USD MILLION) List of Figures FIGURE 1 RESEARCH PROCESS FIGURE 2 PORTERS FIVE FORCES MODEL FIGURE 3 GLOBAL MALIGNANT LYMPHOMA MARKET, BY TYPES FIGURE 4 GLOBAL MALIGNANT LYMPHOMA MARKET, BY TREATMENT FIGURE 5 GLOBAL MALIGNANT LYMPHOMA MARKET, BY REGION FIGURE 6 GLOBAL MALIGNANT LYMPHOMA MARKET: COMPANY SHARE ANALYSIS, 2015 (%) Contact Info:Name: Akash AnandEmail: Akash.Anand@Marketresearchfuture.ComOrganization: Market Research FutureAddress: Market Research Future Magarpatta Road, Hadapsar, Pune - 411028 Maharashtra, IndiaPhone: +1 646 845 9312Source URL: http://marketersmedia.com/malignant-lymphoma-market-research-report-global-forecast-to-2022/198744For more information, please visit https://www.marketresearchfuture.com/reports/malignant-lymphoma-marketSource: MarketersMediaRelease ID: 198744


News Article | February 15, 2017
Site: www.businesswire.com

VANCOUVER, Canada--(BUSINESS WIRE)--Zymeworks Inc. (“Zymeworks”), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, today announced that Dr. Kenneth Hillan, CEO of Achaogen Inc., and Hollings Renton, former CEO and President of Onyx Pharmaceuticals Inc., have been appointed to Zymeworks’ board of directors. Concurrent with the appointment of Dr. Hillan and Mr. Renton, Zymeworks also announces that Dr. Donald Drakeman has retired from the Company’s board of directors, and is transitioning to the position of special advisor to Zymeworks and the board of directors. Dr. Drakeman will continue to contribute his knowledge and perspective to Zymeworks’ management and the board of directors. “ We are delighted to welcome Kenneth and Hollings to our board of directors,” said Ali Tehrani, Ph.D., Zymeworks’ President & CEO. “ Their collective experience working at the highest levels of the biotech and pharmaceutical industries will provide Zymeworks with valuable guidance as we move our lead product candidate, ZW25, through clinical trials and our preclinical assets closer to the clinic. We would also like thank Don for his service on the board since 2010. We look forward to continuing to benefit from his expertise as advisor to Zymeworks” “ Zymeworks’ next-generation therapies aim to advance the practice of medicine and make patients’ lives better, which is one of the most important contributions we can make to the healthcare challenges we face today,” said Dr. Hillan. “ I look forward to working with the board members and the Zymeworks leadership team to support the company’s mission of creating biotherapeutics that allow patients to return home to their loved ones, disease free.” Mr. Renton added, “ I am very pleased to join Zymeworks’ board of directors, and to work with the team to advance their versatile bispecific antibody capabilities. Zymeworks is well-positioned with their lead product candidate in clinical trials, and an exciting preclinical pipeline.” Dr. Kenneth J. Hillan is the CEO of Achaogen Inc. He has served as CEO and a member of the board of directors of Achaogen since October 2011. Prior to joining Achaogen, Dr. Hillan worked at Genentech Inc., a pharmaceutical company and a member of the Roche Group. Dr. Hillan worked in progressively senior roles after joining Genentech in 1994. He was responsible for numerous successful drug approvals and led the medical and scientific strategies for Genentech’s immunology, tissue growth and repair drug portfolio. Dr. Hillan also served on the board of directors of Relypsa Inc., a publicly traded biotechnology company that was acquired in 2016 by Galencia AG for $1.5 billion. Dr. Hillan has an M.B. Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow in the United Kingdom. Dr. Hillan is a Fellow of the Royal College of Surgeons, and a Fellow of the Royal College of Pathologists. Dr. Hillan has authored dozens of scientific publications and is a named inventor on approximately 50 issued patents. Hollings Renton served as CEO and President of Onyx Pharmaceuticals, Inc. from 1993 to 2008 and was the chairperson of the board of directors of Onyx from 2000 to 2008. Onyx was acquired by Amgen Inc. in 2013 for $10.4 billion. Before joining Onyx, Mr. Renton was the President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company. Mr. Renton served in a variety of executive roles at Cetus Corporation from 1983 prior to its acquisition by Chiron in 1991. Mr. Renton currently serves as chairperson of the board of directors of Portola Pharmaceuticals Inc. and on the board of directors of AnaptysBio Inc. Mr. Renton received his M.B.A. from the University of Michigan and his B.S. in Mathematics from Colorado State University. Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. Zymeworks’ suite of complementary therapeutic platforms and its fully-integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly-differentiated product candidates. Zymeworks’ lead product candidate, ZW25, is a novel bispecific antibody currently being evaluated in an adaptive Phase 1 clinical trial. Zymeworks is also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. In addition to Zymeworks’ wholly-owned pipeline, its therapeutic platforms have been further leveraged through multiple strategic partnerships with global biopharmaceutical companies.


- Data Continue to Reinforce the Efficacy and Safety of Selinexor in Patients with Heavily Pretreated Refractory Multiple Myeloma - - Company to Host Dinner Reception and Webcast Event with Interactive Expert Panel Discussion on Monday, December 5, 2016 at 8:15 p.m. PT - NEWTON, Mass., Dec. 04, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced updated results from its Phase 2b STORM study of selinexor (KPT-330), including robust rates and duration of response, compelling overall survival and a favorable safety profile, in patients with heavily pretreated refractory multiple myeloma (MM) at the American Society of Hematology (ASH) 2016 annual meeting held December 3-6, 2016 in San Diego.  Selinexor is the Company’s lead, novel, oral Selective Inhibitor of Nuclear Export (SINE™) compound, in development for the treatment of a variety of malignancies, including MM and acute myeloid leukemia (AML). “The data presented today further support the rationale for selinexor as a promising new treatment for patients with refractory myeloma with no clearly beneficial treatment options,” said Sharon Shacham, PhD, MBA, President and Chief Scientific Officer of Karyopharm. “Based on the exciting STORM data and the existing unmet medical need, we have expanded the study to include additional patients with penta-refractory myeloma and expect to report top-line data from this study in early 2018.” In an oral presentation titled, “Selinexor and Low Dose Dexamethasone in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory MM STORM Study,” Dan T. Vogl, MD, MSCE, Assistant Professor of Medicine, Perelman School of Medicine, University of Pennsylvania, presented updated clinical data from the ongoing Phase 2b STORM study, a single-arm clinical trial evaluating selinexor in combination with low-dose dexamethasone in patients with quad-refractory or penta-refractory myeloma.  Patients with quad-refractory disease have previously received two proteasome inhibitors (PIs) (bortezomib (Velcade®) and carfilzomib (Kyprolis®)) and two immunomodulatory drugs (IMiDs) (lenalidomide (Revlimid®) and pomalidomide (Pomalyst®)), and their disease is refractory to at least one PI, at least one IMiD, and has progressed following their most recent therapy.  Patients with penta-refractory myeloma have quad-refractory disease that is also refractory to an anti-CD38 monoclonal antibody, such as daratumumab (Darzalex®) or isatuximab. ORR=Objective Response Rate (VGPR+PR), CBR=Clinical Benefit Rate (VGPR+PR+MR), VGPR=Very Good Partial Response, PR=Partial Response, MR=Minor Response, SD=Stable Disease, PD=Progressive Disease, NE=Non-Evaluable 1One patient not included, did not have active myeloma All responses were adjudicated by an Independent Review Committee (IRC).  Among the 78 evaluable patients (median seven prior treatment regimens), the overall response rate (ORR) was 21%, and included very good partial responses (VGPR) and partial responses (PR).  Among the 48 patients in the quad-refractory group, the ORR was 21%.  For comparison, in a similar quad-refractory patient population, the anti-CD38 monoclonal antibodies Darzalex® and isatuximab had ORRs of 21% and 20%, respectively.  Among the 30 patients in the penta-refractory group, the ORR was 20%.  Clinical benefit rate (ORR + MR) was 32% (all patients), 29% (quad-refractory), and 37% (penta-refractory).  To the Company’s knowledge, no other agents have reported response rates in patients with penta-refractory MM.  Median overall survival (OS) was 9.3 months for all patients, greater than 11 months (median not reached) for patients with ≥MR, and 5.7 months for patients who did not have any response (≤SD).  Median duration of response (DOR) was 5 months.  Grade ≥3 cytopenias were the most common side effects and were generally not associated with clinical sequellae.  Nausea, anorexia and fatigue were the most common non-hematological side effects, primarily Grades 1 and 2, and were treatable with supportive care and/or dose modification.  There were low rates of Grade ≥3 non-hematologic toxicities, with no new safety signals identified.  In particular, there was one reported case of Grade 4 infection (1.3%), one case of Grade 2 neuropathy (1.3%) and one reported case of sepsis (1.3%). Dr. Vogl commented, “The quad- and penta-refractory populations are continuing to expand as patients live longer and cycle through a variety of treatment options, including immunomodulatory drugs, proteasome inhibitors, or anti-CD38 monoclonal antibodies, before their disease ultimately becomes refractory and non-responsive.  In my experience, selinexor is the first agent to be specifically investigated in this difficult to treat and currently underserved population.  The response rate and duration suggest that selinexor has the potential to be an exciting new option for myeloma treatment.” Karyopharm to Host Multiple Myeloma-focused Dinner Reception and Webcast at ASH 2016 On Monday, December 5, 2016, Karyopharm will host an investor and analyst dinner reception, which will feature a moderated panel discussion with recognized experts in the treatment of MM, updated selinexor data in MM, and a live Q&A session.  Confirmed external speakers include: In addition, Michael Kauffman, MD, PhD, CEO of Karyopharm Therapeutics will be joining. The event will take place during the ASH 2016 annual meeting and interested parties can access a live webcast of the event beginning Monday, December 5, 2016 at 8:15 p.m. PT under “Events & Presentations” in the "Investors" section of the company's website at http://investors.karyopharm.com/events.cfm.  A replay of the webcast will be archived on the company’s website for 90 days following the event. Selinexor (KPT-330) is a first-in-class, oral Selective Inhibitor of Nuclear Export / SINE™ compound. Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus. This reinitiates and amplifies their tumor suppressor function and is believed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells. To date, over 1,800 patients have been treated with selinexor and it is currently being evaluated in several mid- and later-phase clinical trials across multiple cancer indications, including in multiple myeloma in combination with low-dose dexamethasone (STORM) and backbone therapies (STOMP), and in acute myeloid leukemia (SOPRA), diffuse large B-cell lymphoma (SADAL), and liposarcoma (SEAL), among others.  Karyopharm plans to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade®) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma in early 2017.  Additional Phase 1, Phase 2 and Phase 3 studies are ongoing or currently planned, including multiple studies in combination with one or more approved therapies in a variety of tumor types to further inform the Company's clinical development priorities for selinexor. The latest clinical trial information for selinexor is available at www.clinicaltrials.gov. Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).  In addition to single-agent and combination activity against a variety of human cancers, SINE™ compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing.  Karyopharm, which was founded by Dr. Sharon Shacham, currently has several investigational programs in clinical or preclinical development.  For more information, please visit www.karyopharm.com. This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the therapeutic potential of and potential clinical development plans for Karyopharm's drug candidates, including the timing of initiation of certain trials and of the reporting of data from such trials. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. For example, there can be no guarantee that any of Karyopharm's SINE™ compounds, including selinexor (KPT-330), will successfully complete necessary preclinical and clinical development phases or that development of any of Karyopharm's drug candidates will continue. Further, there can be no guarantee that any positive developments in Karyopharm's drug candidate portfolio will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: Karyopharm's results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies, including with respect to the need for additional clinical studies; Karyopharm's ability to obtain and maintain requisite regulatory approvals and to enroll patients in its clinical trials; unplanned cash requirements and expenditures; development of drug candidates by Karyopharm's competitors for diseases in which Karyopharm is currently developing its drug candidates; and Karyopharm's ability to obtain, maintain and enforce patent and other intellectual property protection for any drug candidates it is developing. These and other risks are described under the caption "Risk Factors" in Karyopharm's Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, which was filed with the Securities and Exchange Commission (SEC) on November 7, 2016, and in other filings that Karyopharm may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Velcade® is a registered trademark of Takeda Pharmaceutical Company Limited Revlimid® and Pomalyst® are registered trademarks of Celgene Corporation Kyprolis® is a registered trademark of Onyx Pharmaceuticals, Inc. Darzalex® is a registered trademark of Janssen Biotech, Inc.


News Article | December 21, 2016
Site: www.businesswire.com

SAN DIEGO--(BUSINESS WIRE)--Batu Biologics, a San Diego based immuno-oncology company focused on the development of its tumor angiogenesis targeting immune therapy, ValloVax™, announced today the formation of a Clinical Advisory Board to guide the company in the development of its lead program. “Members of the Batu Biologics Clinical Advisory Board have aligned their vision to assess the clinical feasibility of targeting the tumor vasculature as an effective treatment for solid tumors,” said Samuel C. Wagner, President and CEO of Batu Biologics. “Our goal is to streamline and optimize the clinical development plan for the ValloVax™ program in order to ensure the highest likelihood of patient response in the clinical setting.” “Making advances in a challenging and competitive environment requires a team of experts who can share experiences, information and innovative ideas,” said Dr. Santosh Kesari, Chairman of Batu’s Clinical Advisory Board and Professor at the Pacific Neuroscience Institute and John Wayne Cancer Institute at Providence Saint John’s Health Center. “We are excited to explore various strategies in the areas of predictive biomarkers, personalized therapy, and combination approaches with FDA-approved cancer therapeutics in an effort to ensure the best patient response to the ValloVax™ therapy.” The newly appointed members of the Batu Biologics Clinical Advisory Board are: Dr. Santosh Kesari is a Professor and Chair of Translational Neurosciences and Neurotherapeutics at Pacific Neuroscience Institute and John Wayne Cancer Institute at Providence Saint John’s Health Center. His research investigates the biology of gliomas and brain metastases with the aim of developing new therapeutics. He has a long-standing interest in neural development, cancer stem cells, and neuroimmunology and translational research in these areas to accelerate drug development; Mai is a strategic advisor for biotechnology companies with a focus in oncology and immunotherapy. Dr. Le has over 8 years of oncology drug development experience that includes small molecules, biologics, medical devices and companion diagnostics strategy. She previously served as a medical director at Calithera Biosciences, Plexxikon Inc., Onyx Pharmaceuticals and Proteolix, Inc (acquired by Onyx Pharmaceuticals), and most recently, as the Chief Medical Officer at OncoSec Medical, Inc. Dr. Le obtained a medical degree from the University of Rochester School of Medicine and Dentistry and trained in Laboratory Medicine at University of California, San Francisco; and Boris is currently the President of Clinical and Scientific Affairs at StemImmune Inc. and Adjunct Professor at the Moores UCSD Cancer Center. Dr. Minev previously worked as Director of Immunotherapy and Translational Oncology at Genelux Corporation and was heading the Laboratory of Tumor Immunology and Immunotherapy at the Moores UCSD Cancer Center. Dr. Minev has an extensive experience in Immuno-Oncology and cancer vaccine development, having worked closely on the development of the first tumor vaccine to be approved by a regulatory body (Melacine). Batu Biologics is an immuno-oncology company developing novel gene and cellular based therapies for the treatment of cancer. The Company has filed an IND application for its lead therapeutic, ValloVax™, a multivalent therapeutic vaccine for Non Small Cell Lung Cancer targeting several tumor-angiogenesis associated antigens. ValloVax™ has demonstrated strong inhibition of tumor growth in several histologically distinct tumor models, and the company is currently raising funds that will enable the completion of a Phase I clinical study.

Loading Onyx Pharmaceuticals collaborators
Loading Onyx Pharmaceuticals collaborators